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Objective: The Copenhagen Outpatient ProgrammE – im-
plantable cardioverter defibrillator (COPE-ICD) trial in-
cluded patients with implantable cardioverter defibrillators 
in a randomized controlled trial of rehabilitation. After 6–12 
months significant differences were found in favour of the 
rehabilitation group for exercise capacity, general and men-
tal health. The aim of this paper is to explore the long-term 
health effects and cost implications associated with the re-
habilitation programme; more specifically, (i) to compare 
implantable cardioverter defibrillator therapy history and 
mortality between rehabilitation and usual care groups; (ii) 
to examine the difference between rehabilitation and usual 
care groups in terms of time to first admission; and (iii) to 
determine attributable direct costs.
Methods: Patients with first-time implantable cardioverter 
defibrillator implantation (n = 196) were randomized (1:1) 
to comprehensive cardiac rehabilitation or usual care. Out-
comes were measured by implantable cardioverter defibril-
lator therapy history from patient records and national reg-
ister follow-up on mortality, hospital admissions and costs. 
Results: No significant differences were found after 3 years 
for implantable cardioverter defibrillator therapy or mor-
tality between rehabilitation and usual care. Time to first 
admission did not differ. The cost of rehabilitation was 335 
USD/276 Euro per patient enrolled in rehabilitation. The to-
tal attributable cost of rehabilitation after 3 years was –6,789 
USD/–5,593 Euro in favour of rehabilitation.
Conclusion: No long-term health outcome benefits were 
found for the rehabilitation programme. However, the re-
habilitation programme resulted in a reduction in total at-
tributable direct costs.
Key words: implantable cardioverter defibrillator; rehabilitation; 
economics. 
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IntRoDuctIon
comprehensive cardiac rehabilitation that includes both exercise 
training and psycho-educational components is recommended for 
patients with various heart conditions (1). However, evidence 
from studies of patients with complex conditions, such as those 
with an implantable cardioverter defibrillator (IcD), is sparse (2). 
the copenhagen outpatient ProgrammE – implantable 
cardioverter defibrillator (coPE-IcD) trial, initiated in 2007, 
included 196 IcD patients in a randomized controlled trial 
(Rct) on rehabilitation. the comprehensive cardiac rehabilita-
tion intervention consisted of an exercise training component 
and a psycho-educational component. Primary and secondary 
outcome analyses after 6–12 months showed significantly in-
creased VO
2
 after exercise training compared with usual care 
(mean 23.0 (95% confidence interval (95% cI) 20.9–22.7) 
vs 20.8 ml/min/kg (95% cI 18.9–22.7) in the control group 
(p = 0.004)). Furthermore, comprehensive cardiac rehabilita-
tion significantly increased general health and mental health 
compared with usual care (3). 
Rehabilitation trials often evaluate intermediate or surrogate 
outcomes, such as Vo
2
, if they are too short-term to capture 
all the major health effects and resource implications associ-
ated with the treatment (4). In IcD rehabilitation, evidence of 
reduced risk of ventricular arrhythmia or IcD shock therapy 
is called for (5). Furthermore, hospitalization and healthcare 
costs have seldom been measured (2). Such long-term post-
hoc analyses were pre-planned for the coPE-IcD trial (6).
the objective of this paper is to examine the 3-year long-term 
effects of a comprehensive cardiac rehabilitation programme for 
first-time IcD recipients from the coPE-IcD trial (6); more 
specifically, to: (i) compare IcD therapy history and mortality 
between rehabilitation and usual care groups; (ii) to examine the 
difference between rehabilitation and usual care groups in time 
to first admission; and (iii) to determine attributable direct costs.
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MEtHoDS
the design and methods of the coPE-IcD trial have been described 
in detail elsewhere (6) and are outlined briefly below. 
Setting and intervention
the coPE-IcD trial was conducted in a large university hospital with 
a volume of approximately 300 first-time IcD implantations each year 
during the trial period. Inclusion criteria were: patients who received 
a first-time IcD implant and agreed to participate in the entire pro-
gramme. the intervention included a comprehensive, disease-specific 
cardiac rehabilitation approach, with exercise-training and psycho-
education in addition to usual care. Patients were randomized in a 1:1 
ratio to rehabilitation or usual care.
the approach for the psycho-educational part of the intervention 
was inspired by Parse’s human becoming practice methodologies 
(7). the topics discussed were: events and experiences leading up to 
the IcD implantation, present thoughts and questions, implications 
for everyday life, avoidance behaviour, exercise training, impact 
on family, information (including technical) and recommendations, 
shock and phantom shock, body image, driving and sexuality. the 
patients consulted the nurse in person or by phone once a month for 
6 months, and every 2 months thereafter for the following 6 months. 
the psycho-educational part of the intervention was performed by 2 
nurses, each with 10 years of clinical experience in the care of patients 
with IcDs. three months after the IcD implantation, patients began to 
participate in training sessions twice a week for a 12-week period. the 
physical training programme consisted of an individual consultation 
with a physiotherapist and an individually tailored training programme. 
Patients in the control group followed a usual care programme, which 
included medical follow-up and an invitation to participate in a 2-h 
group session including information about the IcD and exchange of 
experiences among patients. 
All patients in the comprehensive cardiac rehabilitation group par-
ticipated in the exercise training component of the programme: 46% 
exercised in hospital, 26% outside the hospital, and 28% did both. 
A total of 66% of the patients in the usual care group participated 
in a physical training programme, 17% participated in an exercise 
programme at a local hospital, 41% participated in exercise training 
outside the hospital, and 8% did both. trial discontinuation did not 
differ significantly between the intervention and usual care group 
(28.8% vs 30.3% drop-outs; p = 0.64).
because of the nature of rehabilitation, the interventions were open-
labelled to the staff and the patients. A blinded investigator performed 
data collection and administration. blinded outcome analyses were 
conducted.
Outcomes
Descriptive information on age, sex, marital status and citizenship was 
available through national registers. Information on comorbidity was 
obtained from the Danish national Patient Register (nPR) (8), which 
holds information on all admissions to all Danish hospitals since 1977. 
We calculated the tu comorbidity index (9) utilizing information on 
primary and secondary diagnoses from all in- and out-patient contacts 
10 years before the index admission. the following diseases are in-
cluded in the tu score: congestive heart failure, cardiogenic shock, 
arrhythmia, pulmonary oedema, malignancy, diabetes, cerebrovascular 
disease, acute/chronic renal failure, chronic obstructive pulmonary 
disease. All diagnoses are weighted equal. 
Information on IcD indication and disease demographics for par-
ticipants was available from patient records.
Implantable cardioverter defibrillator therapy. IcD therapy history 
was found in patient records up to June 2013. Data registration and 
analysis was blinded. Programming of IcD therapy was done accord-
ing to local practice. Ventricular arrhythmias, anti-tachycardia pacing 
(AtP) and shock therapy were assessed from the time of randomiza-
tion in 2007–2009 until May 2013. IcD therapy during the first 30 
days after IcD implantation was not included, since the intervention 
had not started. All therapies were initially evaluated by a trained 
technician and, subsequently, by an electro-physiologist with special 
competences in device therapy. only appropriate therapy was included. 
In the assessment of appropriate vs inappropriate therapy, standard 
clinical criteria were used, including A-V relationship (if available), 
morphology, regularity of V-signals, and onset of tachycardia.
Mortality and hospital admissions. Information on vital status was 
available through the civil Registration System (10) up to June 2013. 
Admissions after the first 30 days following randomization were avail-
able through the nPR. We followed the participants for 3 years and 
measured and evaluated short-term (1 year) and long-term (3 years) 
effects on admissions. We obtained information on all admissions, first 
admission, first acute (non-elective) admission and first acute heart-
related admission, including only admissions with an International 
classification of Diseases – 10th edition (IcD-10): I00–I99 diagnosis.
Costs. costs attributable to the intervention were calculated by measur-
ing time spent on an average patient in the intervention group, priced by 
the salaries of nurses, physicians and physiotherapists (salaries include 
pension and vacation allowances). A category of other variable costs 
was included (purchase of pulse watches and t-shirts for use during 
the training programme). the calculation only considers operational 
costs and does not include production loss, cost of transportation or 
the costs of buildings (rent) and equipment.
An estimate of the 3-year cost of hospitalization, outpatient treat-
ment (including emergency ward visits), and care in the primary sector 
(general practitioner, physiotherapist and psychologist) for both the 
cardiac rehabilitation group and the usual care group are made. the net 
costs are given by the difference between average costs in the 2 groups. 
the nPR was used to measure the costs of hospital services (hospi-
talization, outpatient treatment and emergency ward visits). the nPR 
contains information on a mean price-rate measured by Diagnosis 
Related groups (DRg) for each contact with hospitals. 
Primary sector costs were measured by use of the Danish national 
Health Service Register (11), which contains information on services 
performed in primary care by practitioners, specialists, physiothera-
pists, chiropractors, etc., which are fully or partially financed by 
public funding. Data on general practitioners, physiotherapists and 
psychologists are included in the analysis. 
costs are measured at 2007 prices by use of price indices on health 
sector costs from Statistics Denmark. Since the study period is 3 
years, second and third year costs are discounted to present values 
by a discount factor of 3%. All costs were measured in 2007 Danish 
kroner, but were translated into uS Dollar Purchasing Power Parities 
(uSD-PPP) and Euro Purchasing Power Parity (EuRo-PPP) by use of 
organisation for Economic co-operation and Development (oEcD) 
state extracts. PPP is used in order to take into account the differences 
in prices between countries. 
Statistical methods
categorical variables are presented as frequencies and percentages. 
continuous variables are presented as mean and standard deviation 
(SD). baseline data are presented as similarities across groups by 
number and percentage. As recommended, no significant test for 
detecting baseline differences was performed (12, 13).
comparison of mortality and IcD therapy history was performed 
by χ2-test for categorical variables and Mann-Whitney U testing for 
non-symmetrical variables. 
time to first admission (general, acute or acute heart-related) was 
analysed by Kaplan–Meier survival analyses and the log-rank test.
Since cost-data are skewed to the right, the 95% confidence interval 
(95% cI) was computed by use of a non-parametric bootstrap analysis 
(1,000 replications). 
All statistical analyses were conducted using SAS 9.3 software.
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Ethics
Patients gave their written informed consent after receiving oral and 
written information. All data was treated in confidence and patients 
were assured anonymity. the trial followed the recommendations of 
the Declaration of Helsinki II. the trial was approved by the regional 
ethics committee (j.nr. H-b-2007-014), the Danish Data Protection 
Agency (j.nr. 2007-41-0932) and registered at clinicaltrials.gov (ID: 
nct00569478). 
RESultS
During the inclusion period, october 2007 to november 2009, 
589 patients received a first-time IcD implantation at the setting. 
A total of 196 patients were included, 99 randomized to the com-
prehensive cardiac rehabilitation and 97 to usual care (Fig. 1). 
the baseline demographics and clinical characteristics of 
the participants (rehabilitation and usual care groups) are 
presented (table I). 
Rehabilitation vs usual care. the number of IcD shocks 
delivered did not differ significantly between rehabilitation 
and usual care groups; a mean of 0.6 vs 0.5 shocks (p = 0.90). 
likewise, no significant difference was found in ventricular 
tachycardia/ventricular fibrillation or AtP (table II).
no significant difference was found in mortality, with 19.2% 
in the rehabilitation group and 12.4% in the control group 
(p = 0.19), and no difference in time to death (p = 0.19). Measur-
ing time to first admission in the total population, 39.8% had a 
hospitalization within 1 year and 67.9% within 3 years. no differ-
ence was found between groups in number of patients with first 
admission (70 vs 63 patients) (p = 0.35) (table III). no significant 
difference was found in number of admissions: intervention 2.6 
vs control 3.2 (p = 0.42) (not shown). likewise, no significant 
difference was found in length of hospital stay between groups: 
intervention 14.3 vs control 13.2 (p = 0.19) (not shown).
Fig. 1. conSoRt (consolidated Standards of Reporting trials) flow-chart.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility 
(n=589) !
Excluded (n=200) 
 
Eligible non-participants: 
Did not want to participate (n=165) 
No reason listed (n=28) 
Randomized  
(n=196) 
Usual care (n=97) Intervention (n=99) 
Completed 6 months (n=76) 
Withdrawal (n=9) 
Death (n=1) 
Completed 3 months (n=86) 
Withdrawal (n=12) 
Death (n=1) !!
Completed 3 months (n=79) 
Withdrawal (n=17) 
Death (n=1)
Completed 12 months (n=71) 
Completed 12 months (n=73) 
Withdrawal (n=3) 
Completed 6 months (n=71) 
Withdrawal (n=8) 
Table I. Demographic and clinical characteristics
Intervention
(n = 99)
usual care
(n = 97)
Female, n (%) 20 (20.2) 20 (20.6)
Age, years, mean (SD) 57.6 (12.9) 56.7 (13.5)
14–49 years, n (%) 24 (24.2) 24 (24.7)
50–59 years, n (%) 24 (24.2) 25 (25.8)
60–69 years, n (%) 31 (31.3) 35 (36.1)
70–86 years, n (%) 20 (20.2) 13 (13.4)
civil status, n (%)
Married 58 (58.6) 58 (59.8)
Divorce 16 (16.2) 13 (13.4)
unmarried 16 (16.2) 21 (21.7)
Widowed 9 (9.1) 5 (5.2)
lVEF, mean, (SD) 73% of total 
population < 35
32.2 (17) 32.7 (18)
nYHA class (n %)
I 30 (30.3) 18 (18.6)
II 42 (42.4) 44 (45.4)
III 24 (24.2) 32 (33.0)
IV 2 (2.0) 1 (1.0)
6-Min Walk test, mean (SD) 420.2 (112.1) 414.7 (118.0)
VO
2
(est), mean (SD) 20.98 (7.98) 20.88 (7.8)
body mass index > 30 (kg/m2), n (%) 24 (24.2) 19 (19.6)
Diseases, n (%)
Atrial fibrillation 27 (27.3) 21 (21.7)
cRt device 14 (14.1) 9 (9.3)
History of ischaemic heart disease 45 (45.5) 57 (58.8)
History of heart failure 76 (76.8) 73 (75.3)
Hypertension 18 (18.2) 23 (23,7)
Diabetes mellitus 12 (12.1) 10 (9.7)
tu comorbidity index, n (%)
tu 0 1 (1.0) 2 (2.1)
tu 1 26 (26.3) 27 (27.8)
tu 2 47 (47.5) 53 (54.6)
tu 3–6 25 (25.3) 15 (15.5)
Indication, n (%)
Primary prophylactic 63 (63.6) 67 (69.1)
Secondary prophylactic 36 (36.4) 30 (30.9)
Ventricular fibrillation
No 75 (75.8) 78 (80.4)
Yes 21 (21.2) 19 (19.6)
Variables used to calculate tu scores are drawn from registers, while all 
other disease demographics are drawn from patient records. SD: standard 
deviation; lVEF: left Ventricular Ejection Fraction; nYHA: new York 
Heart Association class; Vo
2
(est) Estimated oxygen consumption; cRt: 
cardiac Resynchronization theraphy. 
Table II. Comparison of implantable cardioverter defibrillator (ICD) 
therapy history and deaths between comprehensive cardiac rehabilitation 
patients and usual care patients from inclusion up to June 2013. Mean 
follow-up 3.9 years
Intervention usual care
Mean (SD) Q3, P95 Mean (SD) Q3, P95 Pa
Vt/VF 6.4 (28.7) 2, 13 7.8 (37.3) 1, 28 0.57
AtP 8.4 (37.0) 2, 29 13.8 (92.5) 1, 28 0.29
IcD shocks 0.6 (2.0) 0, 4 0.5 (1.5) 0, 3 0.90
n (%) n (%) Pb
Deaths 19 (19.2) 12 (12.4) 0.19
aMann-Whitney U testing whether the 2 distributions differ only with 
respect to the median. bχ2 test. Vt: ventricular tachycardia; VF: ventricular 
fibrillation; AtP: anti-tachycardia pacing; SD: standard deviation; Q3: 
upper quartile; P95: 95% percentile.
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the total cost of the intervention was 335 uSD-PPP/276 
Euro-PPP per patient enrolled in rehabilitation. the total direct 
cost after 3 years in the rehabilitation groups was 19,664 uSD-
PPP/16,199 Euro-PPP vs 26,453 uSD-PPP/21,792 Euro-PPP in 
the control group. the total attributable cost of the intervention 
after 3 years was –6,789 uSD-PPP/–5,593 Euro-PPP (table IV). 
DIScuSSIon
As previously reported by berg et al. (3), significant differ-
ences were found between groups in physical capacity and 
mental health after rehabilitation. the aim of this paper was 
to explore the long-term health effects and cost implications 
associated with the rehabilitation programme. looking at the 
2 groups, rehabilitation and usual care, the long-term follow-
up revealed no difference in IcD shock, mortality or time to 
first admission between the groups. the total attributable cost 
of the intervention was –6,789 uSD-PPP/–5,593 Euro-PPP in 
favour of the intervention. 
Implantable cardioverter defibrillator therapy shock
no difference was found in AtP or IcD shock, which is in ac-
cordance with previous findings in combined programmes (14) 
and from psycho-educational IcD programmes (15–19). look-
ing at the exercise-only programmes, the evidence is somewhat 
conflicting, as the large trial Heart Failure: A controlled trial 
Investigating outcomes of Exercise training (HF-ActIon) 
(n = 1,285 IcD patients) found no difference in IcD shock (20, 
21), but a smaller (n = 82) non-randomized trial found non-
participation in outpatient rehabilitation to be a predictor for 
IcD shock (odds ratio (oR) 4.6, 95% cI 1.5–17.8, p < 0.05) 
(22). Davis et al. adjusted for exercise limitation, but not for 
other co-morbidities that might have confounded the data in 
the non-randomized design. A randomized trial by belardinelli 
(n = 52) of exercise vs no exercise found that 8 patients in the 
control group had sustained Vt, while no Vt events were 
found in the intervention group (23). 
Mortality
Examining mortality, we found no difference between the 
groups, which matches previous findings (20, 23). However, 
findings from Ischemic rehabilitation show that a one metabolic 
equivalent (MEt) higher level of maximal aerobic capacity 
(equivalent to 1 km/h faster running) was associated with a 
13% reduction in mortality (24). Several possible explanations 
exist for not obtaining the same positive effect in IcD patients. 
In the present trial the difference between the 2 groups after 
exercise was 0.6 MEt, which might not have been enough 
to have an effect on mortality. Furthermore, the difference 
between the 2 groups was diluted, since the usual care group 
exercised on their own, which may explain the limited effect 
(3). Furthermore, the cardiac disease, which indicated for IcD 
implantation, may vary and may determine an inhomogeneous 
response to physical and psycho-educational training. 
Admissions
Readmission is considered an indicator of morbidity and qual-
ity and efficiency of care and, from the literature on heart fail-
ure, we know that patient education and home-based follow-up 
reduces readmissions (25). We found no difference in time to 
first admission. none of the previous IcD rehabilitation trials 
reported time to first admission. However, in the Rct by Dun-
bar et al. no difference was found in the number of emergency 
department visits and hospitalizations after 12 months (19), 
which is in accordance with our findings. In the heart failure 
literature readmission rates after 6 months are as high as 45%; 
we found a rate of 39.8% after 1 year and 67.9% after 3 years. 
Table III. Time to first admission, first acute admission and first acute 
heart admission
Intervention
n (%)
usual care
n (%) p-valuea
time to first admission, days
1 year 41 (41.4) 37 (38.1) 0.53
3 year 70 (70.7) 63 (65.0) 0.35
time to first acute admission, days
1 year 34 (34.3) 32 (33.0) 0.56
3 year 57 (57.6) 51 (52.6) 0.19
time to first acute heart admission, days
1 year 26 (26.3) 24 (24.7) 0.37
3 year 42 (42.4) 42 (43.3) 0.40
alog-rank test for intervention group vs usual care group.
Table IV. Net costs of rehabilitation 2007 USD-PPP/Euro-PPP
costs per person
Attributable costs  
(95% cI)
Rehabilitation  
(n = 99)
usual care 
(n = 97)
costs of rehabilitation
uSD-PPP 
Euro-PPP
335
276
335
276
Hospitalization
uSD-PPP 
Euro-PPP
12,955
10,672
20,061
16,526
7,106 (–20,595 to 2,654)
5,854 (–16,966 to 2,187)
outpatient treatment (inc. ER visits)
uSD-PPP 
Euro-PPP
5,825
4,799
5,668
4,669
157 (–1,351 to 1,768)
129 (–1,113 to 1,456)
general 
Practitioner
uSP-PPP 
Euro-PPP
501
413
539
444
–38 (–161 to 83)
–31 (–133 to 69)
Physiotherapist
uSP-PPP 
Euro-PPP
16
13
157
129
–141 (–278 to –28)
–116 (–229 to –23)
Psychologist
uSD-PPP 
Euro-PPP
33
27
28
23
5 (–44 to 56)
4 (–36 to 46)
Total direct costs
uSD-PPP 
Euro-PPP
19,664
16,199
26,453
21,792
–6,789
–5,593
PPP: Purchasing Power Parities; 95% cI: 95% confidence interval; ER: 
emergency room.
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Costs
the total cost of the intervention was 335 uSD-PPP/276 Euro-
PPP per patient. this cost is relatively low compared with 
previous findings of the mean cardiac rehabilitation costs of 
3,671 in 2003-uSD (4,139 in 2007-uSD) (26). oldridge et al. 
found a cost of 1,365 in 2003-uSD (1,539 in 2007-uSD) for 
a combined exercise and behaviour programme (27). using a 
group-/home-based format has been shown to be equally ef-
fective, and the cost savings are evident (26). Furthermore, we 
may have had lower costs using nursing consultations in the 
psycho-educative approach and we did not include the costs of 
housing, equipment and management. We found a lower cost 
of physiotherapy in the rehabilitation group. this could be 
explained by the fact that experimental physiotherapy is cal-
culated into the total cost of rehabilitation in the rehabilitation 
group, whereas outpatient physiotherapy is calculated on its 
own. Another explanation could be that rehabilitation is pre-
ventive for further needs. We found the total attributable cost 
of the coPE–IcD trial to be –6,789 uSD-PPP/–5,593 Euro-
PPP in favour of the intervention. this cannot be explained by 
significantly lower numbers of admissions or length of stay, and 
therefore must be explained by more expensive treatment. the 
programme thus appears to result in a cost saving. none of the 
previous IcD rehabilitation trials have reported net savings. 
Generalizability
External validity is high, since this population was included 
following the guidelines for IcD implantation from 2006. the 
baseline measures were mostly similar to findings from trials 
conducted in the uSA and Europe (15, 28, 19). the use of 
blinded outcome assessment increased the validity of the data. 
Study limitations
Study limitations include the fact that selection bias may exist, 
as we did not include patients if they were already included 
in other trials. looking at the baseline measures it seems as 
though the randomization worked as there are comparable 
values. A slightly higher number of patients in the usual care 
group had a history of ischaemic heart disease and new York 
Heart Association class (nYHA III) than in the rehabilitation 
group; however, no significant difference in 6MWt and Vo
2
 
were seen between groups before the intervention occurred (3). 
the usual care group might have been contaminated by the 
information given during the project inclusion, suggesting that 
psycho-educational assistance and exercise training might be 
beneficial after IcD implantation. this information may have 
led to usual care patients seeking rehabilitation elsewhere. 
collateral intervention occurred when some patients were of-
fered cardiac rehabilitation at their local hospital, which may 
have reduced the effects of the experimental intervention, but 
resulted in conservative estimations of differences, by groups. 
We used register-based follow-up information, which en-
sured close to complete follow-up. 
costs were calculated using average costs at a national level. 
Micro-costing based on accurate resource utilization is likely 
to be more accurate and reliable. use of DRg in pricing of 
hospitalizations may be inadequate in capturing the true benefit 
of the intervention, as a minimization in, for example, bed 
days will not be reflected in a lower overall DRg (4). costing 
of the rehabilitation intervention only included variable costs 
and did not include capital costs, indicating an underestima-
tion of the costs.
Clinical and research implications
We continue to see high readmission rates in this population 
and the beneficial effect of IcD-specific rehabilitation on 
mortality and IcD shock is still poorly investigated. Even 
though the “hard” endpoints, adverse events, did not seem to 
be affected this should be interpreted with caution due to low 
numbers and the explorative nature of these analyses.
However, we found that exercise training, in combination 
with psycho-educational consultations by a nurse, improves 
exercise capacity, general and mental health and seems to 
produce a cost saving over time. there are reasons to believe 
that this approach is beneficial in clinical practice in terms of 
quality of life and from a cost perspective. larger multicentre 
trials designed with adverse events outcomes are needed to 
determine the effects on adverse events. 
In conclusion, no difference in IcD shock, mortality or time 
to first admission was found between the groups. the total 
attributable cost of the intervention was –6,789 uSD/–5,593 
Euro in favour of the intervention.
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